-+ 0.00%
-+ 0.00%
-+ 0.00%

Mersana Therapeutics Announces Phase 1 Data for Lead ADC Candidate Targeting B7-H4 in Cancer Treatment

Benzinga·01/10/2025 11:02:07
Listen to the news

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced positive initial clinical data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin (Emi-Le; XMT-1660), Mersana's lead Dolasynthen ADC candidate targeting B7-H4.